129 related articles for article (PubMed ID: 29034899)
1. Establishment of a human DOA 'plus' iPSC line, IISHDOi003-A, with the mutation in the OPA1 gene: c.1635C>A; p.Ser545Arg.
Zurita-Díaz F; Galera-Monge T; Moreno-Izquierdo A; Corton M; Ayuso C; Garesse R; Gallardo ME
Stem Cell Res; 2017 Oct; 24():81-84. PubMed ID: 29034899
[TBL] [Abstract][Full Text] [Related]
2. Generation of a human iPSC line from a patient with an optic atrophy 'plus' phenotype due to a mutation in the OPA1 gene.
Galera-Monge T; Zurita-Díaz F; Moreno-Izquierdo A; Fraga MF; Fernández AF; Ayuso C; Garesse R; Gallardo ME
Stem Cell Res; 2016 May; 16(3):673-6. PubMed ID: 27346197
[TBL] [Abstract][Full Text] [Related]
3. Derivation of a human DOA iPSC line, IISHDOi006-A, with a mutation in the ACO2 gene: c.1999G>A; p.Glu667Lys.
Cerrada V; García-López M; Moreno-Izquierdo A; Villaverde C; Zurita O; Martin-Merida MI; Arenas J; Ayuso C; Gallardo ME
Stem Cell Res; 2019 Oct; 40():101566. PubMed ID: 31509793
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of genotype-phenotype analysis of OPA1 mutations in autosomal dominant optic atrophy.
Ham M; Han J; Osann K; Smith M; Kimonis V
Mitochondrion; 2019 May; 46():262-269. PubMed ID: 30165240
[TBL] [Abstract][Full Text] [Related]
5. Generation of a human induced pluripotent stem cell line PUMCHi019-A from a dominant optic atrophy patient with an OPA1 mutation.
Sun Z; Wu S; Zhu T; Wei X; Han X; Zou X; Sui R
Stem Cell Res; 2022 Apr; 60():102705. PubMed ID: 35152176
[TBL] [Abstract][Full Text] [Related]
6. OPA1: How much do we know to approach therapy?
Del Dotto V; Fogazza M; Lenaers G; Rugolo M; Carelli V; Zanna C
Pharmacol Res; 2018 May; 131():199-210. PubMed ID: 29454676
[TBL] [Abstract][Full Text] [Related]
7. Pure and syndromic optic atrophy explained by deep intronic OPA1 mutations and an intralocus modifier.
Bonifert T; Karle KN; Tonagel F; Batra M; Wilhelm C; Theurer Y; Schoenfeld C; Kluba T; Kamenisch Y; Carelli V; Wolf J; Gonzalez MA; Speziani F; Schüle R; Züchner S; Schöls L; Wissinger B; Synofzik M
Brain; 2014 Aug; 137(Pt 8):2164-77. PubMed ID: 24970096
[TBL] [Abstract][Full Text] [Related]
8. OPA1 gene therapy prevents retinal ganglion cell loss in a Dominant Optic Atrophy mouse model.
Sarzi E; Seveno M; Piro-Mégy C; Elzière L; Quilès M; Péquignot M; Müller A; Hamel CP; Lenaers G; Delettre C
Sci Rep; 2018 Feb; 8(1):2468. PubMed ID: 29410463
[TBL] [Abstract][Full Text] [Related]
9. Modelling autosomal dominant optic atrophy associated with OPA1 variants in iPSC-derived retinal ganglion cells.
Sladen PE; Jovanovic K; Guarascio R; Ottaviani D; Salsbury G; Novoselova T; Chapple JP; Yu-Wai-Man P; Cheetham ME
Hum Mol Genet; 2022 Oct; 31(20):3478-3493. PubMed ID: 35652445
[TBL] [Abstract][Full Text] [Related]
10. OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes.
Amati-Bonneau P; Valentino ML; Reynier P; Gallardo ME; Bornstein B; Boissière A; Campos Y; Rivera H; de la Aleja JG; Carroccia R; Iommarini L; Labauge P; Figarella-Branger D; Marcorelles P; Furby A; Beauvais K; Letournel F; Liguori R; La Morgia C; Montagna P; Liguori M; Zanna C; Rugolo M; Cossarizza A; Wissinger B; Verny C; Schwarzenbacher R; Martín MA; Arenas J; Ayuso C; Garesse R; Lenaers G; Bonneau D; Carelli V
Brain; 2008 Feb; 131(Pt 2):338-51. PubMed ID: 18158317
[TBL] [Abstract][Full Text] [Related]
11. Deciphering OPA1 mutations pathogenicity by combined analysis of human, mouse and yeast cell models.
Del Dotto V; Fogazza M; Musiani F; Maresca A; Aleo SJ; Caporali L; La Morgia C; Nolli C; Lodi T; Goffrini P; Chan D; Carelli V; Rugolo M; Baruffini E; Zanna C
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3496-3514. PubMed ID: 30293569
[TBL] [Abstract][Full Text] [Related]
12. Autosomal dominant optic atrophy with
Maeda-Katahira A; Nakamura N; Hayashi T; Katagiri S; Shimizu S; Ohde H; Matsunaga T; Kaga K; Nakano T; Kameya S; Matsuura T; Fujinami K; Iwata T; Tsunoda K
Mol Vis; 2019; 25():559-573. PubMed ID: 31673222
[TBL] [Abstract][Full Text] [Related]
13. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion.
Zanna C; Ghelli A; Porcelli AM; Karbowski M; Youle RJ; Schimpf S; Wissinger B; Pinti M; Cossarizza A; Vidoni S; Valentino ML; Rugolo M; Carelli V
Brain; 2008 Feb; 131(Pt 2):352-67. PubMed ID: 18222991
[TBL] [Abstract][Full Text] [Related]
14. Dominant optic atrophy: updates on the pathophysiology and clinical manifestations of the optic atrophy 1 mutation.
Chun BY; Rizzo JF
Curr Opin Ophthalmol; 2016 Nov; 27(6):475-480. PubMed ID: 27585216
[TBL] [Abstract][Full Text] [Related]
15. OPA1 mutations associated with dominant optic atrophy influence optic nerve head size.
Barboni P; Carbonelli M; Savini G; Foscarini B; Parisi V; Valentino ML; Carta A; De Negri A; Sadun F; Zeviani M; Sadun AA; Schimpf S; Wissinger B; Carelli V
Ophthalmology; 2010 Aug; 117(8):1547-53. PubMed ID: 20417568
[TBL] [Abstract][Full Text] [Related]
16. Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy.
Nolli C; Goffrini P; Lazzaretti M; Zanna C; Vitale R; Lodi T; Baruffini E
Mitochondrion; 2015 Nov; 25():38-48. PubMed ID: 26455272
[TBL] [Abstract][Full Text] [Related]
17. Multi-system neurological disease is common in patients with OPA1 mutations.
Yu-Wai-Man P; Griffiths PG; Gorman GS; Lourenco CM; Wright AF; Auer-Grumbach M; Toscano A; Musumeci O; Valentino ML; Caporali L; Lamperti C; Tallaksen CM; Duffey P; Miller J; Whittaker RG; Baker MR; Jackson MJ; Clarke MP; Dhillon B; Czermin B; Stewart JD; Hudson G; Reynier P; Bonneau D; Marques W; Lenaers G; McFarland R; Taylor RW; Turnbull DM; Votruba M; Zeviani M; Carelli V; Bindoff LA; Horvath R; Amati-Bonneau P; Chinnery PF
Brain; 2010 Mar; 133(Pt 3):771-86. PubMed ID: 20157015
[TBL] [Abstract][Full Text] [Related]
18. The association of autosomal dominant optic atrophy and moderate deafness may be due to the R445H mutation in the OPA1 gene.
Amati-Bonneau P; Odent S; Derrien C; Pasquier L; Malthiéry Y; Reynier P; Bonneau D
Am J Ophthalmol; 2003 Dec; 136(6):1170-1. PubMed ID: 14644237
[TBL] [Abstract][Full Text] [Related]
19. The molecular mechanisms of OPA1-mediated optic atrophy in Drosophila model and prospects for antioxidant treatment.
Yarosh W; Monserrate J; Tong JJ; Tse S; Le PK; Nguyen K; Brachmann CB; Wallace DC; Huang T
PLoS Genet; 2008 Jan; 4(1):e6. PubMed ID: 18193945
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive survey of mutations in the OPA1 gene in patients with autosomal dominant optic atrophy.
Thiselton DL; Alexander C; Taanman JW; Brooks S; Rosenberg T; Eiberg H; Andreasson S; Van Regemorter N; Munier FL; Moore AT; Bhattacharya SS; Votruba M
Invest Ophthalmol Vis Sci; 2002 Jun; 43(6):1715-24. PubMed ID: 12036970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
